Texas Pharmacy Exceeds Residency Match Placement Goals

91% Residency Match Placement. National Average: 82%. The University of Texas at Austin College of Pharmacy. American Society of Health-System Pharmacists, 2023 Pharmacy Residency Match.
May 4, 2023
The University of Texas at Austin College of Pharmacy placed in the top ten in the entire country in the percentage of match placements with 91%, compared to the national match placement average of 82%.

Summer Programs of Innovation and Diversity

LEADER/PEPP Program participants and leaders sitting together at an outdoor table for lunch.
September 6, 2022
This summer, the office of Diversity, Equity, Accessibility, and Inclusion (DEAI), hosted two intensive summer research programs: Project Engage Pharmacy Program (PEPP) Camp and the Leadership Through Engagement For the Advancement of Diverse Educational Research (LEADER) Program.

Celebrating the Latest Awards, Appointments and Achievements from the UT Pharmacy Community

Pharmacy building on UT campus
July 5, 2022
From student scholarships to national recognition awards to prestigious appointments, the UT Pharmacy community has a lot to celebrate and be proud of right now.

UT Pharmacy Earns Highest Residency Match Rate in Texas

#1 Residency Match Placement in Texas
April 19, 2022
Pharmacy schools across the country completed their 2022 Phase I and Phase II residency matches for new or upcoming graduates of their Doctor of Pharmacy (Pharm.D.) programs. The University of Texas at Austin College of Pharmacy placed in the top ten of all pharmacy schools in the nation, and number one in Texas.

TxCORE Research Wins PhRMA Foundation Award

Three people smiling.
April 1, 2021
Three researchers from the College of Pharmacy won an award from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. Leticia R. Moczygemba, Pharm.D., Ph.D., Carolyn M. Brown, Ph.D. and Michael Johnsrud, Ph.D., R.Ph. were awarded $5,000 from the PhRMA Foundation for their proposal to advance racial and ethnic representation in value assessments.

Inhaled Niclosamide a Potential Effective Antiviral to Treat COVID-19

An infrared image of nasal spray being administered.
September 29, 2020
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.